In July of last year we wrote a report on Idenix Pharmaceuticals (NASDAQ:IDIX) indicating that a small chance of a potential buyout, at historic HCV takeover multiples, could send Idenix shares at least 146% higher. We liked that at that time the conservative and highly successful investor Seth Klarman's Baupost owned 18.48% of Idenix, the market was pessimistic on IDIX's nucleotide development and that Idenix's management was focusing on the long-term development of all oral pan genotypic treatments for HCV.
Since July, the shares have risen 91% and numerous significant events have occurred and as a result we have modified our thesis. We believe that although a buyout is still not out of the realm of possibility, we...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|